Global Allan-Herndon-Dudley Syndrome Treatment Market, By Treatment Type (Gene Therapy, Hormone Therapy), By End User (Hospital, Specialty Clinics, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024

Code : CMI6559

Pages :140

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Drivers

Increasing Prevalence of AHDS: Increasing prevalence of AHDS is expected to drive the market growth over the forecast period. For instance, according to the data published by the National Library of Medicine, Allan-Herndon-Dudley syndrome appears to be a rare disorder. About 25 families with individuals affected by this condition have been reported worldwide.
Increasing Healthcare Expenditure Globally: Increasing healthcare expenditure globally will aid in the market growth over the forecast period. For instance, according to the data published by the World Health Organization (WHO) on December 8, 2022, the global healthcare spending reached to US$ 9 trillion, which is approximately 11% of the global GDP.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Opportunities

Growing funding and grants for rare diseases research: The increased funding and grants for rare diseases research provides a major opportunity for the global Allan-Herndon-Dudley syndrome (AHDS) market. Rare diseases are often neglected by big pharmaceutical companies due to very small patient sizes and thus low commercial viability. However, rising government support through grants and incentive programs have significantly boosted rare disease research activities in recent years.

Global Allan-Herndon-Dudley syndrome (AHDS) (MCT8 deficiency) Treatment Market - Restraints

Lack of awareness about AHDS: A major factor limiting the growth of the global Allan-Herndon-Dudley syndrome (AHDS) treatment market is lack of awareness about the condition. AHDS is an extremely rare genetic disorder and there is low recognition of its symptoms even within the medical community. Due to the rarity of the disease and limitations in diagnostic testing availability, many cases continue to go undiagnosed. This severely restricts patients' access to potential treatment options.